Orchestra BioMed

Yahoo Finance • last year

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

U.S. FDA granted Investigational Device Exemption (“IDE”) approval to initiate the BACKBEAT pivotal study evaluating AVIM therapy (BackBeat CNT) in hypertensive pacemaker patients BACKBEAT pivotal study on track to start enrollment before... Full story

Yahoo Finance • last year

Orchestra BioMed to Present at Upcoming Investor Conferences

NEW HOPE, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing par... Full story

Yahoo Finance • last year

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an exclusive strategic collaboration for glob... Full story

Yahoo Finance • last year

Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors

FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appoint... Full story

Yahoo Finance • 2 years ago

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

NEW HOPE, Pa., June 26, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing part... Full story

Yahoo Finance • 2 years ago

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

Completed business combination and listing on Nasdaq generating gross proceeds of approximately $70 million BackBeat CNT™ global pivotal study in hypertensive pacemaker patients on track for initiation in the second half of 2023 in collabo... Full story

Yahoo Finance • 2 years ago

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

NEW HOPE, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing part... Full story

Yahoo Finance • 2 years ago

Orchestra BioMed Strengthens Senior Leadership Team

Avi Fischer, M.D., joins as SVP, Medical Affairs and Innovation; J.C. Simeon assumes role of SVP, Quality George Papandreou, Ph.D., promoted to General Manager and SVP, Focal Therapies; Kunal Faldu promoted to VP, Pharmaceutical Developme... Full story